drugset
drugset / Trial / NCT03429933

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

NCT03429933 ↗

Phase 1 Completed 112 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate experimental medication BMS-986278 given to healthy participants.

Timeline

Start
2018-02-07
Primary completion
2019-03-02
Completion
2019-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Admilparant Small molecule — —

Indications

No indication recorded.